natgillin/translations-raw huggingface dataset:
Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
U roku od 60 dana od ostvarenja važnog cilja (u smislu farmakovigilancije ili smanjenja rizika)
within 60 months
unutar 60 mjeseci
Within a 48-day collection period after a single dose of 14C-cabozantinib in healthy volunteers, approximately 81% of the total administered radioactivity was recovered with 54% in faeces and 27% in urine.
Unutar perioda prikupljanja od 48 dana nakon primjene jedne doze 14C- kabozantiniba u zdravih dobrovoljaca, otprilike 81 % od ukupno primijenjene radioaktivnosti je izlučeno, od čega 54 % fecesom i 27 % urinom.
Within a 48-day collection period after a single dose of 14C-cabozantinib in healthy volunteers, approximately 81% of the total administered radioactivity was recovered with 54% in faeces and 27% in urine.
Unutar perioda prikupljanja od 48 dana nakon primjene jedne doze 14C-kabozantiniba u zdravih dobrovoljaca, otprilike 81% od ukupne primjenjene radioaktivnosti je izlučeno, od čega 54% u fecesu i 27% u urinu.
Within a 48-day collection period after a single dose of 14C-cabozantinib in healthy volunteers, approximately 81% of the total administered radioactivity was recovered with 54% in faeces and 27% in urine.
Unutar perioda prikupljanja od 48 dana nakon primjenejedne doze 14C-kabozantiniba u zdravih dobrovoljaca, otprilike 81% od ukupne primjenjene radioaktivnosti je izlučeno, od čega 54% u izmetu i 27% u urinu.
Within a sub-study of PUP-study 060103, ITI-treatments in 11 PUPs were documented.
U okviru podstudije u PUP studiji 060103, zabilježeno je liječenje metodom imunotolerancije u 11 prethodno neliječenih pedijatrijskih bolesnika.
Within each frequency group, adverse reactions are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping adverse reactions are presented in order of decreased seriousness.
Unutar svake skupine učestalosti nuspojave su navedene slijedom prema sve manjoj ozbiljnosti.
Within each frequency grouping adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su navedene slijedom prema sve manjoj ozbiljnosti.
Within each frequency grouping and SOC, adverse reactions are presented in order of decreasing seriousness.
Unutar svake kategorije učestalosti i klasi organskog sustava nuspojave su navedene u padajućem nizu prema ozbiljnosti.
Within each frequency grouping and SOC, adverse reactions are presented in the order of decreasing seriousness.
Unutar iste kategorije učestalosti i organskog sustava nuspojave su navedene u padajućem nizu prema ozbiljnosti.
Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.
Unutar svakog grupiranja po učestalosti i razredu organskog sustava nuspojave su navedene u padajućem nizu prema ozbiljnosti.
Within each frequency grouping in Table 1, adverse reactions are presented in decreasing order of seriousness.
Unutar svake grupe učestalosti u Tabeli 1, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping in Table 2, adverse reactions are presented in decreasing order of seriousness.
Unutar svake grupe učestalosti u Tabeli 2, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, ADRs are presented in order of decreasing seriousness.
Unutar svake skupine po učestalosti, nuspojave su prikazane redoslijedom prema manjoj ozbiljnosti.
Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave prikazane po redu opadajuće ozbiljnosti.
Within each frequency grouping, adverse reactions are listed using MedDRA terminology and presented in order of decreasing seriousness.
Unutar svake skupine po učestalosti, nuspojave su navedene prema MedDRA terminologiji i prikazane slijedom prema opadajućoj ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing frequency.
Nuspojave su unutar pojedinih skupina učestalosti navedene u padajućem nizu prema učestalosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing of seriousness.
Unutar svake skupine učestalosti nuspojave su navedene prema ozbiljnosti, počevši s najozbiljnijima.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Nuspojave su unutar svake skupine učestalosti navedene od najozbiljnije prema manje ozbiljnoj nuspojavi.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Nuspojave su unutar svake skupine učestalosti prikazane s opadanjem ozbiljnosti:
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
U svakoj grupi učestalosti, nuspojave su poredane od ozbiljnijih prema manje ozbiljnim.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti, nuspojave se prikazuju od najučestalije do najmanje učestale.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti, nuspojave su poredane prema padajućem redoslijedu ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake kategorije učestalosti nuspojave su navedene slijedom prema sve manjoj ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su poredane prema padajućem stupnu ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su prikazane prema opadajućoj ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave prikazane po redu opadajuće ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine, učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
Nuspojave su navedene redom po težini unutar svake od skupina učestalosti:
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
Unutar svake skupine učestalosti nuspojave su prikazane po redoslijedu od najozbiljniih prema manje ozbiljnima:
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
Unutar svake skupine učestalosti nuspojave su prikazane po redoslijedu od najozbiljnijih prema manje ozbiljnima:
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:
Unutar svake skupine učestalosti, nuspojave su prikazane prema opadajućoj ozbiljnosti:
Within each frequency grouping, adverse reactions are presented in order of decreasingseriousness.
Unutar pojedine skupine učestalosti, nuspojave su poredane od ozbiljnijih prema manje ozbiljnima.
Within each frequency grouping, adverse reactions are presented in ordxer of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su prikazane silaznim redoslijedom ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Unutar svake skupine po učestalosti nuspojave su navedene slijedom prema sve manjoj ozbiljnosti, prema sljedećem dogovoru: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Unutar svake grupe incidencije, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su prikazana u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
U skupinama učestalosti nuspojava, prvo su navedene najozbiljnije nuspojave, nakon kojih slijede manje ozbiljne.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
U svakoj skupini prema učestalosti, nuspojave su navedene silaznim slijedom prema ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar iste kategorije učestalosti nuspojave su navedene od težih prema lakšima.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar pojedine skupine učestalosti nuspojave su poredane od ozbiljnijih prema manje ozbiljnima.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake grupe nuspojave su navedene prema svojoj ozbiljnosti, od ozbiljnijih prema manje ozbiljnima.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti nuspojave su prikazane prema silazećem nizu ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake kategorije učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, neželjeni učinci prikazani su prema ozbiljnosti, silaznim redosljedom.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su navedene prema ozbiljnosti, padajućim redoslijedom.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su navedene prema smanjenju ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su prikazane od ozbiljnijih prema manje ozbiljnjim.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su prikazane prema smanjenju ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake su skupine učestalosti, nuspojave su navedene u padajućem nizu prema ozbiljnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: Adult and Elderly
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti: Odrasle i starije osobe
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: Adults and elderly
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti: Odrasle i starije osobe
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: Nervous system disorders
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti: Poremećaji živčanog sustava
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1000 to < 1/100); rare (> 1/10,000 to < 1/1,000): not known (cannot be estimated from the available data).
Unutar svake skupine prema učestalosti, nuspojave su navedene padajućim slijedom prema njihovoj ozbiljnosti: vrlo često (> 1/10); često (> 1/100 i < 1/10); manje često (> 1/1000 i < 1/100); rijetko (> 1/10,000 i < 1/1000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1000 to < 1/100); rare (> 1/10,000 to < 1/1,000); not known (cannot be estimated from the available data).
Unutar svake skupine prema učestalosti, nuspojave su navedene padajućim slijedom prema njihovoj ozbiljnosti: vrlo često (> 1/10); često (> 1/100 i < 1/10); manje često (> 1/1000 i < 1/100); rijetko (> 1/10,000 i < 1/1,000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100) and not known (cannot be estimated from the available data).
Unutar svake grupe učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100) and not known (cannot be estimated from the available data).
Unutar svake grupe učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Unutar svake grupe incidencije nuspojave su poredane prema incidenciji, najčešće prve .
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Unutar svake grupe incidencije nuspojave su poredane prema incidenciji, najčešće prve.
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Unutar svake grupe incidencije, nuspojave su poredane prema incidenciji, najčešće prvoj.
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Unutar svake grupe učestalosti, nuspojave su poredane prema učestalosti, najčešće su navedene prve.
Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent first.
Unutar svake grupe učestalostinuspojave su poredane prema učestalosti, najčešće prve.
Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake grupe učestalosti, nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake klase organskog sustava i skupine učestalosti nuspojave su navedene prema opadajućoj ozbiljnosti.
Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svakog organskog sustava i skupine učestalosti, nuspojave su prikazane redoslijedom prema sve manjoj ozbiljnosti.
Within each system organ class, adverse reactions are listed under headings of frequency using the categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); not known (cannot be estimated from the available data).
Unutar svakog organskog sustava, nuspojave su navedene prema sljedećim kategorijama učestalosti pojavljivanja: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each system organ class, adverse reactions are presented in order of decreasing seriousness.
U svakom razredu sustava organa, nuspojave su prikazane redoslijedom smanjivanja ozbiljnosti.
Within each system organ class, adverse reactions are ranked by frequency.
Unutar svakog organskog sustava nuspojave su razvrstane po incidenciji.
Within each system organ class, adverse reactions with the same frequency are presented in order of decreasing seriousness.
U svakom razredu organskog sustava nuspojave iste učestalosti su predstavljene u padajućem nizu prema ozbiljnosti.
Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first.
Unutar svakog organskog sustava nuspojave su poredane po učestalosti, pri čemu su najučestalije nuspojave navedene prve.
Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first.
Unutar svakog organskog sustava, nuspojave na lijek su poredane po učestalosti, pri čemu su najučestalije nuspojave navedene prve.
Within each system organ class, the adverse reactions are ranked by frequency category with the most common first.
Unutar svakog organskog sustava nuspojave su navedene prema kategoriji učestalosti, počevši od najčešćih.
Within each weight range the entire contents of the correct size pipette should be deposited on the dog’s skin.
Unutar svakog raspona težine cijeli sadržaj pipete ispravne veličine treba nanijeti na psećoj koži.
Within its shelf life, the unopened product may be stored at or below 25°C for up to 3 months without being refrigerated again and must be discarded if it has not been used after 3 months.
Unutar roka valjanosti, neotvoreni lijek može se čuvati na temperaturi od ili ispod 25 °C do 3 mjeseca bez ponovnog odlaganja u hladnjak i mora se zbrinuti ako nije iskorišten nakon 3 mjeseca.
Within its shelf-life and for the purpose of ambulatory use, the patient may remove the product from the refrigerator and store it at room temperature (not above 25°C) for one single period of up to 7 days.
Unutar roka valjanosti i u svrhu kućne primjene, bolesnik može izvaditi lijek iz hladnjaka i čuvati ga na sobnoj temperaturi (ne iznad 25°C) jednokratno u trajanju do 7 dana.
Within its shelf-life, the medicine may be stored at or below 25°C for up to 3 months without being refrigerated and must be discarded if it has not been used after 3 months.
Unutar roka valjanosti, lijek se može čuvati na temperaturi od ili ispod 25 °C do 3 mjeseca bez odlaganja u hladnjak i mora se zbrinuti ako nije iskorišten nakon 3 mjeseca.
Within its shelf-life, the medicine may be stored at or below 25°C for up to 3 months without being refrigeratedand must be discarded afterwards.
Unutar roka valjanosti lijek se smije čuvati na temperaturi od ili ispod 25 °C najviše 3 mjeseca bez ponovnog stavljanja u hladnjak, te se mora zbrinuti nakon tog razdoblja.
Within its shelf-life, the product may be removed from the refrigerator for a single period of up to 3 months at a temperature not above 25°C, without being refrigerated again.
Unutar roka valjanosti, lijek može biti izvan hladnjaka tijekom jednokratnog razdoblja do 3 mjeseca na temperaturi koja ne prelazi 25°C, bez ponovnog odlaganja u hladnjak.
Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
Ako je prošlo manje od 12 sati od uobičajenog termina uzimanja lijeka: bolesnik treba odmah uzeti dozu, a sljedeću dozu treba uzeti prema uobičajenom rasporedu.
Within muscle tissue this includes increasing glycogen, fatty acid, glycerol and protein synthesis and amino acid uptake, while decreasing glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid output.
U mišićnom tkivu oni pospješuju sintezu glikogena, masnih kiselina, glicerola i proteina te pohranu aminokiselina, dok istodobno smanjuju glikogenolizu, glukonoegenezu, ketogenezu, lipolizu, katabolizam proteina i otpuštanje aminokiselina iz stanice.
Within studies, this effect is sustained also after prolonged periods of follow–up.
U ispitivanjima je taj učinak održan i nakon dugotrajnih razdoblja praćenja.
within the
unutar
Within the 24 months shelf life, after thawing, unopened vials can be stored at 2 - 8C and protected from light, for up to 30 days.
Unutar 24-mjesečnog roka valjanosti, nakon odmrzavanja, neotvorene bočice mogu se čuvati na temperaturi od 2-8°C i zaštićene od svjetlosti najdulje 30 dana.
Within the clinical development program, oral maintenance antiarrhythmic therapy was halted for a minimum of 2 hours after BRINAVESS administration.
U okviru programa kliničkog razvoja, terapija održavanja oralnim antiaritmicima bila je obustavljena na najmanje 2 sata nakon primjene lijeka BRINAVESS.
Within the clinical trials, anaphylaxis or serious reactions that necessitated treatment discontinuation were very rare.
U kliničkim su ispitivanjima anafilaksija ili ozbiljne reakcije koje su zahtijevale prekid liječenja bile vrlo rijetke.
Within the designated system organ classes, the adverse drug reactions are listed under headings of frequency and using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Unutar svakog organskog sustava nuspojave su razvrstane prema učestalosti pojavljivanja prema sljedećoj konvenciji: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the following table, adverse reactions are ranked under the MedDRA frequency classification:
U tablici u nastavku, nuspojave su razvrstane prema MedDRA kategorijama učestalosti:
Within the four clinical studies discussed in this PUSA, ‘pallor’ or ‘over-whitening of the skin’ has been reported.
Unutar četiri klinička ispitivanja o kojima se raspravljalo u ovom PSUSA izvješću, zabilježeno je 'bljedilo' ili 'prekomjerno blijeđenje kože'.
Within the highest quartile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).
Unutar najvišeg kvartila prema centru omjer hazarda s rivaroksabanom u odnosu na varfarin iznosio je 0,74 (95% CI, 0,49 do 1,12).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).
Unutar najviše trećine prema centru omjer hazarda s rivaroksabanom naspram varfarina bio je 0,642 (95% CI: 0,277 - 1,484).
Within the highest tertile according to centre, the hazard ratio with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).
Unutar najviše trećine prema centru omjer hazarda s rivaroksabanom naspram varfarina bio je 0,69 (95% CI: 0,35 - 1,35).
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su navedene prema i učestalosti (broj bolesnika u kojih se očekuje pojava navedene reakcije), sukladno sljedećim kategorijama: vrlo često ( ≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).